Treatment of young children with HIV infection: Using evidence to inform policymakers

PLoS Medicine

Volumn 9, Issue 7, 2012, Pages

  Prendergast, Andrew J ^a,b,c   Penazzato, Martina ^b   Cotton, Mark ^d   Musoke, Philippa ^e   Mulenga, Veronica ^f   Abrams, Elaine J ^g   Gibb, Diana M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c ZVITAMBO Project   (Zimbabwe)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e MULAGO HOSPITAL   (Uganda)

^f University Teaching Hospital   (Zimbabwe)

^g Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHILD; DEATH; DISEASE COURSE; DRUG TREATMENT FAILURE; HEALTH CARE POLICY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; SIDE EFFECT; TOXICITY; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADMINISTRATIVE PERSONNEL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; EVIDENCE-BASED MEDICINE; HEALTH PLAN IMPLEMENTATION; HEALTH PLANNING GUIDELINES; HEALTH POLICY; HIV INFECTIONS; HUMANS;

EID: 84864484003     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001273     Document Type: Article

References (29)

1. World Health Organization, UNAIDS (2011) Global HIV/AIDS response: progress report 2011. Available: http://www.unaids.org/en/resources/publications/2011/. Accessed 18 March 2012.
2. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236-1243.
3. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, et al. (2010) Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 304: 1082-1090.
4. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, et al. (2012) Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis Epub ahead of print 15 March 2012.
5. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. (2010) Antiretroviral treatment for children with peripartum nevirapine exposure. N Eng J Med 363: 1510-1520.
6. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, et al. (2011) NVP- vs LPV/r-based ART among HIV+ infants in resource-limited settings: the IMPAACT P1060 Trial. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA.
7. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, et al. (2008) Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 22: 1333-1343.
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, et al. (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Eng J Med 359: 2233-2244.
9. Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb DM, (2012) Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev In press.
10. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, et al. (2005) Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 293: 2221-2231.
11. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, et al. (2004) Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 39: 1692-1698.
12. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, et al. (2004) A trial of three antiretroviral regimens in HIV-1-infected children. N Eng J Med 350: 2471-2480.
13. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach Geneva WHO Available: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed 24 March 2012.
14. Barker PM, Mphatswe W, Rollins N, (2011) Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 56: e45-e48.
15. Cotton M, Violari A, Gibb D, Otwombe K, Josipovic D, et al. Early ART followed by interruption is safe and is associated with better outcomes than deferred ART in HIV+ infants: final results from the 6-year randomized CHER trial, South Africa. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA.
16. Meyer-Rath G, Violari A, Cotton M, Ndibongo B, Brennan A, et al. (2010) The cost of early vs. deferred paediatric antiretroviral treatment in South Africa- a comparative economic analysis of the first year of the CHER trial. XVIII International AIDS Conference; Vienna, Austria.
17. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Eng J Med 356: 135-147.
18. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273-283.
19. Judd A, The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord (2011) Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS 25: 2279-2287.
20. Best BM, Capparelli EV, Diep H, Rossi SS, Farrell MJ, et al. (2011) Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 58: 385-391.
21. McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, et al. (2009) Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 28: 1127-1129.
22. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, et al. (2011) Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 306: 70-78.
23. Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, et al. (2010) Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis 51: 1081-1089.
24. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, et al. (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Eng J Med 363: 1499-1509.
25. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25: 479-492.
26. UNAIDS (2011) Countdown To Zero: global plan towards elimination of new HIV infections among children by 2015 and keeping their mothers alive Geneva UNAIDS Available: http://www.unaids.org/en/. Accessed 16 March 2012.
27. UNAIDS (2011) The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. Available: http://data.unaids.org/pub/Outlook/2010/20100713_outlook_treatment2_0_en.pdf. Accessed on 24 March 2012.
28. Lallemant M, Chang S, Cohen R, Pecoul B, (2011) Pediatric HIV-a neglected disease? N Eng J Med 365: 581-583.
29. Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Ngugi E, et al. (2012) Treatment interruption in infants following 24 months of empiric ART: Kenya. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA.